PD-L1 Expression Continuum and Response Probability
CheckMate 057: Nivolumab vs Docetaxel in Previously Treated NSQ NSCLC
9
31
37
41
15
12
13
7
100
80
20
60
0
40
Baseline PD-L1 expression level
<1%
≥1%
≥50%
≥10%
10/108
n/N
15/101
38/123
15/123
32/86
10/79
27/66
3/46
ORR (%) [95% CI]
Nivolumab
Docetaxel
Estimated response probability
a
(%)
Baseline PD-L1 expression level (%)
100
75
25
50
0
1
100
10
20
30
40
50
60
70
80
90
95% CI
95% CI
Nivolumab
(n = 121)
Docetaxel
(n = 115)
Estimated
a
Peters S, et al. WCLC 2016
